Why the study?
Does L-NAME or L-arginine prevent doxorubicin-induced cardiotoxicity in a preclinical model?
Does L-NAME or L-arginine prevent doxorubicin-induced cardiotoxicity in a preclinical model?
L-NAME, a nitric oxide synthase inhibitor, attenuates doxorubicin-induced cardiotoxicity in a preclinical model, suggesting a potential role for NO inhibition in cardio-protection.
Hypothesis-generating for NOS inhibition against doxorubicin cardiotoxicity; leaves open translation to human cardioprotection.
The effects of Nomega-nitro-L-arginine methylester (L-NAME) and L-arginine on cardiotoxicity that is induced by doxorubicin (Dox) were investigated. A single dose of Dox 15 mg/kg i.p. induced cardiotoxicity, manifested biochemically by a significant elevation of serum creatine phosphokinase (CPK) activity [EC 2.7.3.2]. Moreover, cardiotoxicity was further confirmed by a significant increase in lipid peroxides, measured as malon-di-aldehyde (MDA) in cardiac tissue homogenates. The administration of L-NAME 4 mg/kg/d p.o. in drinking water 5 days before and 3 days after the Dox injection significantly ameliorated the cardiotoxic effects of Dox, judged by the improvement in both serum CPK activity and lipid peroxides in the cardiac tissue homogenates. On the other hand, the administration of L-arginine 70 mg/kg/d p.o. did not protect the cardiac tissues against the toxicity that was induced by the Dox treatment. The findings of this study suggest that L-NAME can attenuate the cardiac dysfunction that is produced by the Dox treatment via the mechanism(s), which may involve the inhibition of the nitric oxide (NO) formation. L-NAME may, therefore, be a beneficial remedy for cardiotoxicity that is induced by Dox and can then be used to improve the therapeutic index of Dox.
No takes yet. Share an insight, caveat, or question.
Mansour et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: